Obesity and chronic venous diseases as comorbid pathologies in surgical practice
https://doi.org/10.21518/akh2025-018
Abstract
This review is devoted to the modern view of morbid obesity in the development and treatment of chronic venous diseases (CVD) and includes a compilation of data from domestic and foreign literature, including clinical recommendations of WHO and the Russian Ministry of Health. Currently, there is evidence of an aggravating association of morbid obesity (BMI ≥ 40 kg/m2 or with BMI ≥ 35 kg/m2 in the presence of serious complications associated with obesity) with CVD, while both conditions are widespread in the world with a tendency to progress. Often they exist simultaneously in the patient, which increases the risk of vascular events and radically changes the management tactics of such a patient. The outcomes of developing remodeling in the walls of the veins in the form of, first of all, an inflammatory process are reflected in the arterial bed, which increases the relevance of the issue and emphasizes the need for timely correction and, mainly, adequate surgical treatment. The results of various surgical interventions at venous incompetence worsen along with an increase in BMI. In this regard, today, patients with extremely (≥40 kg/m2) high BMI are primarily recommended to treat not venous insufficiency, but to correct weight, including through bariatric surgery, which is due to the ineffectiveness of the reverse approach.
About the Authors
A. G. Khitar’yan
Clinical Hospital “RZD-Medicine”;
Rostov State Medical University
Russian Federation
Russian Federation
Aleksandr G. Khitar’yan, Head of the Surgical Department, 92a, Varfolomeev St., Rostov-on-Don, 344011;
Dr. Sci. (Med.), Professor, Honoured Doctor of the Russian Federation, Head of the Department of Surgical Diseases No. 3, 29, Nakhichevansky Lane, Rostov-on-Don, 344022
A. A. Orekhov
Clinical Hospital “RZD-Medicine”;
Rostov State Medical University
Russian Federation
Russian Federation
Alexey A. Orekhov, Doctor of the Highest Category, Surgeon of the Surgical Department, 92a, Varfolomeev St., Rostov-on-Don, 344011;
Cand. Sci. (Med.), Associate Professor of the Department of Surgical Diseases No. 3, 29, Nakhichevansky Lane, Rostov-on-Don, 344022
E. Ya. Kirtanasova
Rostov State Medical University
Russian Federation
Russian Federation
Elena Ya. Kirtanasova, Postgraduate Student of the Department of Surgical Diseases No. 3,
29, Nakhichevan Lane, Rostov-on-Don, 344022
V. N. Kislyakov
Clinical Hospital “RZD-Medicine”
Russian Federation
Russian Federation
Vasiliy N. Kislyakov, Cand. Sci. (Med.), Surgeon of the Surgical Department,
92a, Varfolomeev St., Rostovon-Don, 344011
A. V. Mezhunts
Clinical Hospital “RZD-Medicine”;
Rostov State Medical University
Russian Federation
Russian Federation
Arut V. Mezhunts, Surgeon of the Surgical Department, 92a, Varfolomeev St., Rostovon-Don, 344011;
Associate Professor of the Department of Surgical Diseases No. 3, 29, Nakhichevansky Lane, Rostov-on-Don, 344022
K. S. Veliev
Clinical Hospital “RZD-Medicine”
Russian Federation
Russian Federation
Kamil S. Veliev, Cand. Sci. (Med.), Surgeon of the Surgical Department,
92a, Varfolomeev St., Rostov-onDon, 344011
References
1. Shevela AI, Usov SA, Markina VA. Obesity and Chronic venous insufficiency: from risk factors to pathogenesis. Flebologiya. 2019;13(3):220–224. (In Russ.) https://doi.org/10.17116/flebo201913031220.
2. Dedov II, Mel’nichenko GA, Shestakova MV, Troshina EA, Mazurina NV, Shestakova EA et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and Metabolism. 2018;15(1):53–70. (In Russ.) https://doi.org/10.14341/omet2018153-70.
3. Alferova VI, Mustafina SV. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and Metabolism. 2022;19(1):96–105. (In Russ.) https://doi.org/10.14341/omet12809.
4. Deol ZK, Lakhanpal S, Franzon G, Pappas PJ. Effect of obesity on chronic venous insuficiency treatment outcomes. J Vasc Surg: Venous and Lymphatic Dis. 2020;8:617–628. https://doi.org/10.1016/j.jvsv.2020.04.006.
5. Youn YJ, Lee J. Chronic venous insufficiency and varicose veins of the lower extremities. Korean J Intern Med. 2019;34(2):269–283. https://doi.org/10.3904/kjim.2018.230.
6. Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.
7. Khitaryan AG, Burtsev SS, Orekhov AA, Veliev KS, Ledenev AA. Chronic venous disease in overweight people with morbid obesity. Flebologiya. 2022;16(1):17–22. (In Russ.) https://doi.org/10.17116/flebo20221601117.
8. Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, Kirienko AI. Prevalence and risk factors for chronic venous disease in the general Russian population. Eur J Vasc Endovasc Surg. 2017;54(6):752–758. https://doi.org/10.1016/j.ejvs.2017.08.033.
9. Akar İ, İnce İ, Aslan C, Benli İ, Demir O, Altındeger N et al. Oxidative stress and prolidase enzyme activity in the pathogenesis of primary varicose veins. Vascular. SAGE Publications Ltd. 2018;26(3):315–321. https://doi.org/10.1177/1708538117741764.
10. Vuylsteke ME, Thomis S, Guillaume G, Modliszewski ML, Weides N, Staelens I. Epidemiological study on chronic venous disease in Belgium and Luxembourg: prevalence, risk factors, and symptomatology. Eur J Vasc Endovasc Surg. 2015;49(4):432–439. https://doi.org/10.1016/j.ejvs.2014.12.031.
11. Robertson LA, Evans CJ, Lee AJ, Allan PL, Ruckley CV, Fowkes FG. Incidence and risk factors for venous reflux in the general population: Edinburgh vein study. Eur J Vasc Endovasc Surg. 2014;48(2):208–214. https://doi.org/10.1016/j.ejvs.2014.05.017.
12. Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FG, Evans CJ. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh vein study. J Vasc Surg: Venous and Lymphatic Dis. 2015;3(1):18–26. https://doi.org/10.1016/j.jvsv.2014.09.008.
13. Stoyko YuM, Kiriyenko AI, Zatevakhin II, Pokrovskiy AV, Karpenko AA, Zolotukhin IA et al. Diagnostics and Treatment of Chronic Venous Disease: Guidelines of Russian Phlebological Association. Flebologiya. 2018;12(3):146–240. (In Russ.) https://doi.org/10.17116/flebo20187031146.
14. Апханова ТВ, Булатов ЛВ, Вахратьян ПЕ, Волков АМ, Волков АС, Гаврилов ЕК и др. Варикозное расширение вен нижних конечностей: клинические рекомендации. 2021. Режим доступа: https://diseases.medelement.com/disease/варикозное-расширение-вен-нижнихконечностей-кп-рф-2021/17016?ysclid=m8o50vyz1e646294210.
15. Baliyan V, Tajmir S, Hedgire SS, Ganguli S, Prabhakar AM. Lower extremity venous reflux. Cardiovasc Diagn Ther. 2016;(6):533–543. https://doi.org/10.21037/cdt.2016.11.14.
16. Sushkou S, Samsonava I, Galishevich M. Expression of the proinflammatory marker CD34 in varicose leg veins. Phlebologie. 2015;44(1):19−23. https://doi.org/10.12687/phleb2221-1-2015.
17. de Mello Porciunculla M, Braga Diamante Leiderman D, Altenfeder R, Siqueira Barbosa Pereira C, Fioranelli A, Wolosker N, Castelli V. Clinical, ultrasonographic and histological findings in varicose vein surgery. Rev Assoc Med Bras Associacao Medica Brasileira. 2018;64(8):729–735. https://doi.org/10.1590/1806-9282.64.08.729.
18. Halkar M, Medina Inojosa J, Liedl D, Wysokinski W, Houghton DE, Wennberg PW et al. Calf muscle pump function as a predictor of all-cause mortality. Vasc Med. 2020;25(6):519–526. https://doi.org/10.1177/1358863X20953212.
19. Mahapatra S, Ramakrishna P, Gupta B, Anusha A, Para MA. Correlation of obesity & comorbid conditions with chronic venous insufficiency: results of a single-centre study. Indian J Med Res. 2018;147(5):471–476. https://doi.org/10.4103/ijmr.IJMR_1844_16.
20. Vines L, Gemayel G, Christenson JT. The relationship between increased body mass index and primary venous disease severity and concomitant deep primary venous reflux. J Vasc Surg: Venous and Lymphatic Dis. 2023;1(3):239–244. https://doi.org/10.1016/j.jvsv.2012.10.057.
21. Hotoleanu C. Association between obesity and venous thromboembolism. Med Pharm Rep. 2020;93(2):162–168. https://doi.org/10.15386/mpr-1372.
22. Movahed MR, Khoubyari R, Hashemzadeh M, Hashemzadeh M. Obesity is strongly and independently associated with a higher prevalence of pulmonary embolism. Respir Investig. 2019;57(4):376–379. https://doi.org/10.1016/j.resinv.2019.01.003.
23. Dutta EH, Burns RN, Pacheco LD, Marrs CC, Koutrouvelis A, Koutrouvelis GLO. Lower extremity blood flow velocity in obese versus nonobese pregnant women. Am J Perinatol. 2020;37(4):384–389. https://doi.org/10.1055/s-0039-1679867.
24. Gianesini S, De Luca L, Feodor T, Taha W, Bozkurt K, Lurie F. Cardiovascular insights for the appropriate management of chronic venous disease: a narrative review of implications for the use of venoactive drugs. Adv Ther. 2023;40(12):5137–5154. https://doi.org/10.1007/s12325-023-02657-0.
25. Shevlyukova TP, Chabanova NB, Ermakova AA, Ermakova PA. Construction of an integral indicator for complex assessment and analysis of risk factors for varicose veins of the lower extremities during pregnancy. Perm Medical Journal. 2020;37(6):25–32. (In Russ.) https://doi.org/10.17816/pmj37625-32.
26. Rakhimzhanova RI, Kozhakhmetova ZhJ, Ozerman A. Assessment of risk factors for thrombosis in ICU patients with COVID-19. Science & Healthcare. 2023;25(1):16–25. (In Russ.) https://doi.org/10.34689/SH.2023.25.1.002.
27. Chang SL, Huang YL, Lee MC, Hu S, Hsiao YC, Chang SW. Association of varicose veins with incident venous thromboembolism and peripheral artery disease. JAMA. 2018;319:807–817. https://doi.org/10.1001/jama.2018.0246.
28. Gianesini S, De Luca L, Feodor T, Taha W, Bozkurt K, Lurie F. Cardiovascular insights for the appropriate management of chronic venous disease: a narrative review of implications for the use of venoactive drugs. Adv Ther. 2023;40(12):5137–5154. https://doi.org/10.1007/s12325-023-02657-0.
29. Huwait E, Mobashir M. Potential and therapeutic roles of diosmin in human diseases. Biomedicines. 2022;10(5):1076. https://doi.org/ 10.3390/biomedicines10051076.
30. Araujo-León JA, Ortiz-Andrade R, Hernández-Baltazar E, Hernández-Núñez E, Rivera-Leyva JC, Yáñez-Pérez V. A pharmacokinetic study of Mix-160 by LC-MS/MS: oral bioavailability of a dosage form of citroflavonoids mixture. Molecules. 2022;27(2):391. https://doi.org/ 10.3390/molecules27020391.
31. Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Pharmacology of diosmin, a citrus flavone glycoside: an updated review. Eur J Drug Metab Pharmacokinet. 2022;47(1):1–18. https://doi.org/10.1007/s13318-021-00731-y.
32. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon® ) on improving individual symptoms, signs and quality oflife in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebocontrolled trials. Int Angiol. 2018;37(2):143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.
33. Rabe E, Blanc-Guillemaud V, Onselaer MB, Blangero Y, Yaltirik HP, Nicolaides A. Reduction oflower-limb edema in patients with chronic venous disease by micronized purified flavonoid fraction: a systematic literature review and meta-analysis. Int Angiol. 2023;42(6):488–502. https://doi.org/10.23736/S0392-9590.23.05084-8.
34. Xiong H, Wang J, Ran Q, Lou G, Peng C, Gan Q et al. Hesperidin: a therapeutic agent for obesity. Drug Des Devel Ther. 2019;13:3855–3866. https://doi.org/10.2147/DDDT.S227499.
35. Morshedzadeh N, Ramezani Ahmadi A, Behrouz V, Mir E. A narrative review on the role of hesperidin on metabolic parameters, liver enzymes, and inflammatory markers in nonalcoholic fatty liver disease. Food Sci Nutr. 2023;11(12):7523–7533. https://doi.org/10.1002/fsn3.3729.
36. Taheri A, Mobaser SE, Golpour P, Nourbakhsh M, Tavakoli-Yaraki M, Yarahmadi S, Nourbakhsh M. Hesperetin attenuates the expression of markers of adipose tissue fibrosis in pre-adipocytes. BMC Complement Med Ther. 2023;23(1):315. https://doi.org/10.1186/s12906-023-04152-z.
37. Martínez Noguera FJ, Alcaraz PE, Carlos Vivas J, Chung LH, Marín Cascales E, Marín Pagán C. 8 weeks of 2S-Hesperidin supplementation improves muscle mass and reduces fat in amateur competitive cyclists: randomized controlled trial. Food Funct. 2021;12(9):3872–3882. https://doi.org/10.1039/d0fo03456h.
38. Martínez-Noguera FJ, Alcaraz PE, Carlos-Vivas J, Marín-Pagán C. 8 weeks of 2S-hesperidin prevents a decrease in pO2 at submaximal intensity in amateur cyclists in off-season: randomized controlled trial. Food Funct. 2023;14(6):2750–2767. https://doi.org/10.1039/d2fo03007a.
39. Bogachev VYu, Boldin BV, Varich GA, Dzhenina OV, Abdosh R. Chronic venous diseases and obesity: pathogenetically based treatment and prevention options. Ambulatornaya Khirurgiya. 2024;21(1):64–73. (In Russ.) https://doi.org/10.21518/akh2024-014.
40. Donahue PMC, Crescenzi R, Petersen KJ, Garza M, Patel N, Lee C. Physical therapy in women with early stage lipedema: potential impact of multimodal manual therapy, compression, exercise, and education interventions. Lymphat Res Biol. 2022;20(4):382–390. https://doi.org/10.1089/lrb.2021.0039.
41. Shaalan W, El Emam A, Lotfy H, Naga A. Clinical and hemodynamic outcome of morbidly obese patients with severe chronic venous insufficiency with and without bariatric surgery. J Vasc Surg: Venous and Lymphatic Dis. 2021;9(5):1248–1256.e2. https://doi.org/10.1016/j.jvsv.2021.01.005.
42. Yang GK, Parapini M, Gagnon J, Chen JC. Comparison of cyanoacrylate embolization and radiofrequency ablation for the treatment of varicose veins. Phlebology. 2019;34(4):278–283. https://doi.org/10.1177/0268355518794105.
43. Sugarman HJ, Sugarman EL, Wolfe L, Kellum JM Jr, Schweitzer MA, DeMaria EJ. Risks and benefits of gastric bypass morbidly obese patients with severe venous stasis disease. Ann Surg. 2001;234:41–46. https://doi.org/10.1097/00000658-200107000-00007.
44. Moussa O, Ardissino M, Muttoni S, Faraj A, Tang A, Khan O et al. Long-term incidence and outcomes of obesity-related peripheral vascular disease after bariatric surgery. Langenbecks Arch Surg. 2021;406:1029. https://doi.org/10.1007/s00423-020-02066-9.
45. de Medeiros Alves Fernandes WR, Lins EM, Rocha FA, de Oliveira Buril G, de Barros E Silva ETAGB, de Andrade Souza Caldas RP et al. Effect of obesity and bariatric surgery on saphenous veins. Obes Surg. 2023;33(3):821–825. https://doi.org/10.1007/s11695-023-06469-7.
Review
For citations:
Khitar’yan A.G., Orekhov A.A., Kirtanasova E.Ya., Kislyakov V.N., Mezhunts A.V., Veliev K.S. Obesity and chronic venous diseases as comorbid pathologies in surgical practice. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2025;22(1):146-152. (In Russ.) https://doi.org/10.21518/akh2025-018
Views:
545
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 